VAN ANDEL RESEARCH INSTITUTE
Patent Owner
Stats
- 17 US PATENTS IN FORCE
- 2 US APPLICATIONS PENDING
- Jan 25, 2018 most recent publication
Details
- 17 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 386 Total Citation Count
- Jun 22, 2001 Earliest Filing
- 25 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
8563513 Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of useMar 26, 10Oct 22, 13[A61K, C07K]
8466339 with early onset degenerative joint disease and role as a tumor suppressorJun 15, 06Jun 18, 13[A01K, G01N]
8309315 Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methodsAug 25, 08Nov 13, 12[C12P, C12N, G01N, C07K]
8173670 Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoidsJan 13, 10May 08, 12[A01N]
7968762 Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)Jul 12, 05Jun 28, 11[C12N, A01K, G01N]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2015/0376,252 Norrin Mutant Polypeptides, Methods of Making and Uses ThereofAbandonedFeb 20, 14Dec 31, 15[A61K, C07K]
2014/0302,068 MicroRNA Biomarkers for Diagnosing Parkinson's DiseaseAbandonedSep 10, 12Oct 09, 14[C12Q]
2014/0274,768 Glycoforms of MUC5AC and Endorepellin and Biomarkers for Mucinous Pancreatic CystsAbandonedMar 10, 14Sep 18, 14[G01N]
2013/0237,441 Mig-6 Knockout Mice and Elucidation of Association of Mig-6 With Early Onset Degenerative Joint Disease and Role As A Tumor SuppressorAbandonedFeb 28, 13Sep 12, 13[C12Q]
2013/0045,952 ABA Receptor Agonists for Increased Plant Stress ResistanceAbandonedAug 17, 12Feb 21, 13[A61K, A61P]
2013/0005,598 Methods for Diagnosing The Malignant Potential of Pancreatic Cystic LesionsAbandonedDec 30, 10Jan 03, 13[G01N, A61B, C40B]
2012/0100,157 Biomarker and Method for Predicting Sensitivity to MET InhibitorsAbandonedOct 11, 11Apr 26, 12[A61K, C12Q, G01N, A61P, C40B]
2012/0045,459 Methods for Treating Autophagy-Related DisordersAbandonedMay 05, 10Feb 23, 12[A61K, C12Q, C12N, G01N, A61P]
2011/0237,497 COMPOSITIONS OF A V-ATPASE INHIBITOR IN COMBINATION WITH A GLUCOCORTICOID RECEPTOR LIGAND AND METHODS OF USEAbandonedNov 18, 10Sep 29, 11[A61K, C12N, A61P]
7622267 Low-density lipoprotein receptor 6 (LRP6) as a mammary stem cell marker and related methodsExpiredMay 30, 07Nov 24, 09[G01N]
7612035 Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanomaExpiredJun 20, 05Nov 03, 09[A61K]
2009/0215,686 NK1-BASED POLYPEPTIDES AND RELATED METHODSAbandonedMar 05, 08Aug 27, 09[A61K, C12N, G01N, A61P, C07K]
2008/0124,362 Domain II Mutants Of Anthrax Lethal FactorAbandonedOct 03, 05May 29, 08[A61K, C12N, G01N, C07K]
2007/0297,980 Geldanamycin and Derivatives Inhibit Cancer Invasion and Identify Novel TargetsAbandonedMar 28, 05Dec 27, 07[A61K, C07D, A61P]
2007/0297,985 METHOD AND COMPOSITION FOR ENHANCING BONE FORMATIONAbandonedApr 10, 07Dec 27, 07[A61K, G01N, A61P]
2007/0111,265 Ligands for mineralocorticoid receptor (MR) and methods for screening for or designing MR ligandsAbandonedNov 14, 06May 17, 07[A61K, G01N, G06F]
2007/0026,059 Ligands for orphan nuclear hormone receptor steroidogenic factor-1 (SF-1)AbandonedFeb 06, 06Feb 01, 07[A61K, G01N]
2007/0020,234 Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factorAbandonedJul 07, 04Jan 25, 07[A61K]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.